Targeting strategies for oxaliplatin-induced peripheral neuropathy: clinical syndrome, molecular basis, and drug development

Table 1 Chemotherapeutics and the incidence or prevalence of reported neuropathies

Chemotherapy	Class	Approximate incidence/prevalence of CIPN (%)	References
Oxaliplatin	Platinum-based chemotherapeutics	Acute: 85–96; chronic wide range: 40–93	[3]
Cisplatin	Platinum-based chemotherapeutics	12–85	[3]
Paclitaxel	Taxanes	61–92	[2, 4]
Bortezomib	Proteasome inhibitor	47–80	[2, 4]
Vincristine	Vinca alkaloids	14–70	[5]
Thalidomide	Immunomodulatory drugs	21–50	[6]

ISSN: 1756-9966